Fiala

Peptide library › Cancer & imaging

LTX-315

Also known as Ruxotemitide

In clinical trialsCancer & imaging

Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.

What people use it for

What LTX-315 does in the body

An oncolytic peptide that punches holes in cancer cell membranes. The dying cells release signals that help the immune system recognise the cancer, including tumours elsewhere in the body.

Strength of evidence

Moderate: early-phase trials showed injected tumours shrinking and immune activation.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA.

How it's taken

Route: Injection directly into tumours (in trials)

How long it lasts (half-life): Not relevant: acts locally in the tumour

Keep track of LTX-315 privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open LTX-315 in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Cancer & imaging